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Novelty and Impact 
International medical travel has received little attention in oncology, and retinoblastoma. We 
report that 5% of a comprehensive global cohort of patients with newly diagnosed 
retinoblastoma were treated abroad in 2017. This may help save the eye and vision but also 
may delay treatment, a risk exacerbated during pandemics and other crises when international 
borders are shut down. These findings should promote co-ordinated global provision of 
specialist eye cancer centres and emergency travel arrangements. 
 
Abbreviations 
GATS - World Trade Organization’s General Agreement on Trade in Services  
Rb – retinoblastoma 
TNM classification - (American Joint Committee on Cancer Tumor, Node, Metastasis category)  
WHO – World Health Organization 
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Abstract 
 
Early diagnosis and treatment of retinoblastoma (Rb), the most common intraocular malignancy, can 
save both the child’s life and vision. However, access to services and hence chances for survival and 
preserving the eye and its vision vary widely across the globe. Some families have to, or make a 
choice to, leave their home country to seek planned medical treatment abroad.  
We aimed to investigate how frequently this cross border travel occurs and the factors associated 
with it.  
A total of 278 Rb centers in 153 countries were recruited to participate in a global cross-sectional 
analysis of newly diagnosed Rb patients in 2017.  
Number and proportions of children who travelled from their home country for treatment were 
analysed by country, continent, socio-economic stratum, and clinical and demographic features. 
The cohort included 4,351 new patients of whom 223 (5.1%, 95% CI 4.5-5.8) were taken across 
country borders for planned medical treatment. Independently significant predictors of travelling 
across borders included: being from a country with a smaller population, being from a country 
classified as low socioeconomic status, having bilateral Rb, and having intra-ocular disease without 
extra-ocular spread.  
The factors that determine international travel for retinoblastoma treatment are complex and 
deserve further investigation. We may need to rethink the way services are delivered in the light of 
the threat of severe curtailment of international travel from pandemics like COVID-19.  
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Introduction 
Retinoblastoma (Rb) is a rare and potentially deadly childhood cancer. Its incidence (except for 
familial cases) is thought to be constant across the globe, ranging from 1:16,000-18,000 live births 
(1). In most countries, because of the need for specialist care, only a single or a few specialized Rb 
centers exist. In Europe, for example, there is a single center in France in Paris, two in the UK, both in 
England (London and Birmingham), and three in Russia, all in Moscow. Such a policy of centralized 
tertiary centers likely improve outcomes for those that reach them in time but may also impede 
access and impose high travel burdens on patients, which can lead to poorer quality of life, more 
advanced disease at diagnosis, later treatment, and worse prognosis (2,3).  
We recently recruited a global cohort of more than 4,000 newly diagnosed patients with Rb from 
over 150 countries and reported presentation patterns by national-income level. The dataset has 
been published on an online repository (4).  Establishment of this cohort has led to increased 
interest in global networking, expertise sharing, and planning for a rare disease such as Rb. In 
particular, a desire to work together has emerged to aid access to specialist treatment centres for 
children from low income countries, currently a major problem as discussed in our report (5). 
We previously described gross disparity in the stage of disease at presentation at specialist centres 
by socioeconomic status of the country of origin (5). Likely reasons include lack of awareness of the 
urgency and poor access to specialist services because of the expense and travel distance. Because 
tumour stage at the time of presentation to the specialist centre is likely to have a profound effect 
on visual prognosis and survival (6), it is important to investigate these accessibility issues in detail. 
In some cases travel to a foreign country is necessary or preferred by families. 
Medical travel is the second mode of trade in health services as defined in the World Trade 
Organization’s General Agreement on Trade in Services (GATS) (7). It is a growing and still poorly 
understood phenomenon. As part of our initiative to investigate and improve access to Rb 
treatment, we have investigated the subgroup of families who travel to a different country for 
planned primary medical treatment. We aimed to investigate for the first time the frequency of this 
phenomenon and the factors which influence it. 
 
Methods 
We collected data as an international, multicenter, one-year cross-sectional cohort, as described in 
detail previously, of 4351 children, median age 30.5 months, interquartile range 14-86 months,  45% 
female, 85% from low and middle income countries (5). Rb treatment centers from all continents 
reported all new patients with Rb who presented between 1 January 2017 and 31 December 2017. 
The recruitment steps are summarized in figure 1. Country populations and classification by 
national-income level was obtained from the World Population Prospects 2017 (8) of the United 
Nations.  
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The study was approved by the London School of Hygiene & Tropical Medicine Institutional Review 
Board (reference no. 14574), who granted a waiver of informed consent. Participating centres 
applied to and received ethics clearance in their countries according to local institutional guidelines.  
The number and percentage (with 95% confidence interval) of children taken across national borders 
for planned primary Rb treatment were calculated for the whole sample, and then by continent and 
socioeconomic category of the country of origin. Mean ages of children who were treated abroad  
rather than in their country of origin were compared. Percentages of children travelling across 
country borders for treatment were then compared by 4 other binary variables which we judged to 
be possible effectors: sex, family history of Rb, bilaterality of Rb, and extraocular spread of Rb. 
Patient and country related factors found to be associated with travelling across borders were 
entered into a multiple logistic regression model to investigate their independence (SPSS). Cases 
where one or more of these data were missing were eliminated case by case for the univariate 
analyses. Only cases with a complete set of data for significant predictor variables were included in 
the regression model. 
 
Results 
The overall number out of the 4,351 children who were taken across country borders for planned 
primary medical treatment for Rb was 223 (5.1%, 95% CI 4.5-5.8). The number and percentage of 
children being taken across borders divided by possible geographic, socioeconomic, and clinical 
predictors are shown in table 1. The phenomenon was seen most commonly in Europe (9.6%), 
followed by Africa, Asia and then Latin America (1.9%). Cross border travel was not seen in North 
America or Oceania. 
The numbers and percentages of children travelling across borders by country of origin are shown in 
table 2 together with the socioeconomic status of each country and number of specialist Rb centers 
in each country from where at least one child travelled. Fifty-three of the 223 children (24%) who 
travelled abroad came from countries with no specialist Rb center. 
Multiple logistic regression analysis analysis showed that independently significant predictors for 
children to travel across borders for planned primary treatment of Rb were: being from a smaller 
country (population less than the median of 97.5M) (p<0.0005), being from a country classified as 
low socioeconomic status (P<0.001), having bilateral Rb (p<0.0005) and having intra-ocular Rb 
without extra-ocular spread (P<0.015). These remained independent predictors for travel whether 
or not the 53 children from countries without a center were included. (table 3) 
Figures 2-4 show the patterns of cross border travel by continent, socioeconomic status, and world 
geography. Europe where cross border travel was seen most commonly is shown in greater detail in 
figure 5. 
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Discussion 
A number of complex factors are thought to influence decisions to travel for medical treatment. A 
World Health Organization (WHO 2006) resolution on international trade and health (WHA 59.26) 
urged member states to understand the implications of international trade and trade agreements 
for health and to address the issues through policies and regulations (9). The increasing acceptance 
of health care internationalism is evident in Europe, where greater patient mobility led to an EU 
Directive on cross-border health care (10). Although international travel within Europe was common 
in our cohort, the recent corona virus disease-19 (COVID-19) crisis has imposed almost a complete 
halt to obtaining planned medical care abroad and, indeed, sometimes even in their home country,  
and has resulted in some children having had to have both eyes removed in their home country 
instead of receiving chemotherapy at a specialist center abroad (unpublished data, IDF). This 
illustrates the importance of studying the patterns of this type of cross border travel. 
There are few data reporting numbers of ‘medical tourists’ in general (11) and for cancer or for 
conditions of childhood. Recent work on the ethics of commercial medical tourism has noted that 
oncology generated £378 million in London in 2017 with most patients coming from the Middle East 
but also from Europe, China and the USA (12). The United Arab Emirates were estimated to have 
spent US$163 in 2013 on international cancer care (13) Patients coming from less developed 
countries are often sponsored by the government of their country of origin despite the fact that in 
some cases local treatment is available (14). Review of the literature on this subject reveals more 
financial data than epidemiological or clinical since it is a large industry. The authors highlight 
ethical, medical and communication issues that arise from this practice (13,14). In our experience of  
Rb, familes are often seeking treatment that is not available to them, at any cost, in their home 
country; or the government is sending them abroad because they have too few patients to justify a 
specialist centre.  They are desperate to save the eye, and to avoid enucleation, and collect money 
from any source to make this happen.  
We used our large global cohort data to systematically investigate some of the factors that might be 
associated with the decision to travel to another country for planned primary Rb treatment, and our 
data shows that geographic, socioeconomic and clinical factors likely all play a part. 
We found differences in the frequency of cross border travel for primary treatment of Rb in the five 
continents of the world. Children from North America and Oceania were not shown to travel abroad 
although it is well known that in the United States may families may travel long distances to the 
specialized center of their choice. Increasing proportions of travelling abroad were seen from Latin 
America and the Caribbean to Asia, Africa and, finally, Europe which had the highest percentage of 
cross border travel. This resulted largely from the fact that of the 20 European countries, 6 smaller 
ones did not have a specialist Rb center, necessitating planned and usually government-organized 
travel across borders. The rational need for and the number of Rb centers within an individual 
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country are related to the annual number of new patients. Enough centers with an appropriate 
geographic distribution are needed to conveniently serve all patients within a country, but the ideal 
number is limited by the need for each expert center to gain enough experience of managing Rb 
(15). Rare disease networks can potentially help achieve a compromise by pooling resources across 
countries and centres for rare diseases like Rb. Incidence trends can be detected earlier and risk 
factors appropriately investigated. Survival might potentially be improved by early diagnosis, new 
treatments, and improved case management (16). Almost all the European children who crossed 
borders (48/50) travelled to another European country. The ease and relatively low cost of travel 
within much of Europe may in part explain why it was most common and practical there., In 
addition, European Union (EU) law specifically gives the right to obtain treatment from another EU 
country (including Switzerland) if a treatment is not available in the home country. The Rarecare 
study in Europe showed a higher level of centralization of treatment of Rb compared to other 
tumours though there was intercountry variation (16). However the multiple logistic regression 
analysis showed that smaller population size was an overriding reason for high rates of travel in 
Europe (since when it was included in the model, Europe ceased to be an independent factor) . 
Also in other continents, the large majority of cross border travel occurred within the continent, with 
additional small numbers of people from Africa travelling to Europe or Asia, and small numbers of 
people from Asia travelling to Europe or North America. 
The effect of socioeconomic status was not as clear as the geographic differences, except for the 
lowest band of countries from which children were more likely to travel. This is a separate factor 
from the geographic continent because none of the European countries belong to this lowest socio-
economic band. Figure 3 shows that, although most of this movement across socioeconomic 
gradient was from poorer to richer countries, 25 patients from outside the lowest socioeconomic 
grouping travelled to poorer countries. These 25 were mainly in North Africa and the Middle East, 
Amman in Jordan and Tunis being the most frequent treatment centres. 
We have previously reported that, in European countries, travel distance from home to a Rb center 
is not a barrier to early diagnosis (17). European patients travelled on average more than 400 km 
and yet >60% presented with a tumor confined to the globe (American Joint Committee on Cancer 
Tumor, Node, Metastasis category cT2) (18), whereas African patients travelled on average of less 
than 200 km, yet >80% presented with advanced disease, some with extraocular tumour spread (cT3 
or worse), suggesting that factors other than geographic distance to retinoblastoma center play a 
role in late disease diagnosis. This is reinforced by the findings of this study, which show that the 
patients who managed to cross borders had less advanced disease, in that they were less likely to 
have spread beyond the eye. 
Clinical predictors of travelling for primary treatment of Rb were bilateral tumor and tumor confined 
to the eye. Patients with both eyes affected might be more likely to be taken abroad for treatment 
either because of the feeling that bilateral disease is more serious or because it is always 
accompanied by risk of blindness. However extraocular disease might also have been expected to be 
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seen as more serious disease, but fewer children with extraocular spread were taken abroad. This 
may be because conventional chemotherapy and enucleation to manage this stage of the disease 
are more widespread than are intra-arterial chemotherapy and brachytherapy to save an eye with 
advanced or otherwise vision-threatening intraocular disease, or it may be that families with the 
resources to travel out of their country seek care and are diagnosed earlier and before extra-ocular 
spread. In Lausanne, Switzerland, for instance, 9 of the 18 patients originated from countries 
without an Rb specialist, 5 from a country where intra-arterial chemotherapy is not available (which 
may be the only way of avoiding removal of the eye) and 4 chose to be treated in Lausanne for other 
reasons (FM personal communication). 
Limitations of our data have previously been reported (4) and include the convenience sampling 
technique, predominantly retrospective reporting, and socioeconomic stratification by country 
rather than individual families. This stratification of possible factors associated with international 
travel by country as opposed to by individual family factors limits the power of this study to 
investigate the complex reasons behind the decision to travel. In addition there were potential 
factors which we did not directly investigate eg national guidelines, population size, distance to 
travel. In addition, this study is focused on first line treatment tourism which is capturing only a part 
of the medical tourism of retinoblastoma. During the same year (2017) Lausanne received 33 new 
non-Swiss patients coming for second or third opinion, having already received some treatment 
elsewhere, whereas only a separate 18 treatment naïve patients were reported in this cohort (FM 
personal communication).  In addition the sample is incomplete. Figure 1 shows that 20 invited 
centers did not report patients. This included 6 who had no cases that year, 6 who had cases but did 
not report (including one high volume center in North America and one in Africa) and 8 for whom we 
have no information. Nevertheless, it is the largest and most globally comprehensive cohort of 
retinoblastoma patients so far reported.  
In summary, we have shown that around 5% of the world population of retinoblastoma patients 
travel across national borders for diagnosis and primary treatment and that the factors that 
influence this are complex and include geography, population size, ease of international travel, 
national government guidelines, availability of domestic specialist services, socioeconomic status of 
the home country, and the clinical features of the disease. The combination of these factors varies 
from continent to continent. We recommend further investigation of this phenomenon: better 
understanding of the patterns of cross border travel and the factors influencing them will help us, as 
a global retinoblastoma community, prioritize which countries require specialist centers and regions 
of the world where cross border travel for medical reasons, especially for rare and lethal disease,  
need to be made politically and economically easier. Furthermore, the community may need to 
rethink the way services are delivered in the light of the threat of severe curtailment of international 
travel from pandemics like COVID-19. 
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Figure legends.  
Figure 1 – Summary of recruitment to the 2017 Global retinoblastoma cohort 
Figure 2 – Intercontinental travel for planned primary retinoblastoma treatment 
Figure 3 – Travel for planned primary retinoblastoma treatment across socio-economic strata  
Figure 4 – Intercountry travel for planned primary retinoblastoma treatment illustrated on a world 
map  
Figure 5 - Intercountry travel for planned primary retinoblastoma treatment within Europe 
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Table 1 Characteristics of 223 Retinoblastoma patients who travelled outside their country of 
residency for treatment and 4,128 who were treated in their country of residency, 2017 
 Sub-group #1: number (%) of 
patients that travelled across 
borders  
Sub-group #2: number of 
patients diagnosed and 
treated within their 
country of residence 
Significance 
(for 2 way 
comparisons) 
 Number % (95% CI) Number  
Total 223 5.1% 
(4.5-5.8) 
4128  
Continent (by increasing rate of cross border travel)  
          Oceania None  17  
          North America None  200 
          LAC 6 1.9% 
(0.4-3.5) 
306 
          Asia 99 4.3% 
(3.5-5.2) 
2177 
          Africa 68 6.6% 
(5.1-8.2) 
956 
          Europe 50 9.6% 
(7.0-12.1)) 
419 
National income level (by increasing rate of cross border travel)  
          Lower-middle 77 4.0% 
(3.1-4.8) 
1863  
          High 28 4.2% 
(2.7-5.7) 
638 
          Upper-middle 63 5.2% 
(3.9-6.4) 
1144 




          Male 129 ( 5.4% 
(4.5-6.3) 
2246  
          Female 94 4.8% 
(3.8-5.7) 
1882  
Family history of Rb P=0.83 
          Yes 11 5.5% 
(2.3-8.7) 
188  




          Unilateral 126 4.2% 
(3.5-4.9) 
2884  
          Bilateral 97 7.2% 1244  
This article is protected by copyright. All rights reserved.
(5.8-8.6) 
Extraocular Rb at presentation P=0.045 
          Yes 36 3.9% 
(2.6-5.1 
890  
          No 187 5.5% 
(4.8-6.3) 
3189  
Age at presentation: P=0.71 
 % 95% CI % 95%CI  
mean in months 25.7 (22.8-28.5) 27.0 (26.3-27.7)  
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Table 2. Travel across borders: 223 patients from 73 countries who were diagnosed with Rb 
outside their country of residence. 
Country National 
income level 
N = patients that travelled 
across borders  
(total no. from country, %) 






3 (13, 23.1) 1 
Angola Lower-
middle 
1 (17, 5.9) None 
Burkina Faso Low 2 (29, 6.9) 1 
Burundi Low 14 (26, 53.8) 1 
Cote d'ivoire Lower-
middle 
5 (32, 15.6) 1 
Democratic Republic of Congo Low 5 (39, 12.8) 3 
Egypt Lower-
middle 
1 (129, 0.8) 3 
Gambia Low 2 (2, 100) None 
Guinea Low 1 (1, 100) None 
Guinea-Bissau Low 1 (1, 100) None 
Liberia Low 1 (1, 100) None 
Libya Upper-
middle 
8 (11, 72.7) 1 
Mali Low 2 (27, 7.4) 1 
Morocco Lower-
middle 
3 (29, 10.3) 3 
Mozambique Low 1 (14, 7.1) 2 
Nigeria Lower-
middle 
2 (130, 1.5) 10 
Republic of the Congo Lower-
middle 
1 (1, 100) None 
Rwanda Low 1 (14, 7.1) 1 
Sénégal Low 1 (27, 3.7) 1 
Sierra Leone Low 1 (1, 100) None 
Somalia Low 1 (1, 100) None 
South Africa Upper-
middle 
1 (59, 1.7) 7 
South Sudan Low 5 (5, 100) None 
Sudan Lower-
middle 
5 (13, 38.5) 1 
Asia 
Afghanistan Low 13 (27, 48.1) 3 
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Azerbaijan Upper-
middle 
3 (5, 60.0) 1 
Bangladesh Lower-
middle 
13 (161, 8.1) 3 
Bhutan Lower-
middle 
1 (1, 100) None 
Cambodia Lower-
middle 
1 (22, 4.5) 1 
India Lower-
middle 
1 (558, 0.2) 18 
Indonesia Lower-
middle 
3 (159, 1.9) 9 
Iraq Upper-
middle 
17 (64, 10.9) 7 
Kazakhstan Upper-
middle 
5 (30, 16.7) 1 
Kuwait High 2 (2, 100) None 
Kyrgyzstan Lower-
middle 
4 (9, 44.4) 1 
Malaysia Upper-
middle 
1 (21, 4.8) 1 
Nepal Low 3 (22, 13.6) 1 
Oman High 1 (1, 100) None 
Pakistan Lower-
middle 
1 (184, 0.5) 6 
Saudi Arabia High 4 (5, 80.0) 1 
State of Palestine Lower-
middle 
6 (6, 100) None 
Syria Lower-
middle 
9 (9, 100) None 
Tajikistan Lower-
middle 
1 (1, 100) None 
Turkmenistan Upper-
middle 
2 (2, 100) None 
United Arab Emirates High 1 (1, 100) None 
Vietnam Lower-
middle 
2 (108, 1.9) 2 
Yemen Lower-
middle 




2 (4, 50.0) 1 
Andorra High 1 (1, 100) None 




2 (3, 66.7) 1 
Austria High 2 (9, 22.2) 1 
Bosnia and Herzegovina Upper-
middle 
3 (3, 100) None 
Bulgaria Upper-
middle 
5 (11, 45.5) 1 
France High 1 (49, 2.0) 1 
Georgia Lower-
middle 
1 (2, 50.0) 1 
Greece High 4 (4, 100) None 
Italy High 2 (31, 6.5) 3 
Kosovo Lower-
middle 
2 (2, 100) None 
Lithuania High 1 (2, 50.0) 1 
Malta High 1 (1, 100) None 
Moldova Lower-
middle 
3 (3, 100) None 
Netherlands High 1 (16, 6.3) 1 
Norway High 5 (9, 55.6) 1 
Romania Upper-
middle 
4 (8, 50.0) 1 
Russia Upper-
middle 
3 (84, 3.6) 3 
Serbia Upper-
middle 
2 (9, 22.2) 2 
Ukraine Lower-
middle 
5 (34, 14.7) 2 
LAC 
Antigua and Barbuda High 2 (2, 100) None 
Jamaica Upper-
middle 
1 (3, 33.3) 1 
Mexico Upper-
middle 
1 (32, 3.1) 2 
Paraguay Upper-
middle 
1 (10, 10.0) 3 
Peru Upper-
middle 
1 (74, 1.4) 5 
Puerto Rico High 1 (1, 100) None 
* Only countries from where at least one child travelled are included here.  
Rb – retinoblastoma, LAC - Latin America and the Caribbean 
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Table 3. Multiple logistic regression analysis showing independently significant predictors predictors 
of international travel (n=4250; 53 children from countries with no centre (since they would inevitably 
have travelled), and those with incomplete data for these 4 risk factors were excluded from this 
analysis  
 Predicting factor Significance Odd ratio 95% CI for odds 
ratio 
Patient related Intraocular Rb 0.015 0.572 0.365-0.895 
Bilateral Rb <0.0005 0.549 0.400-0.753 
Country related Small population 
size 
<0.0005 0.180 0.115-0.281 
Low income status 0.001 0.501 0.338-0.742 
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298 Rb centers from 134 countries 
contacted
278 Rb centers from 130 countries 
joined in the study and reported on 
4,395 new Rb patients from 153 
countries
20 Rb centers did not join in
Duplicate reporting on 14 patients
30 patients did not fulfil the 
inclusion criteria1
Study sample: 4,351 patients from 
153 countries
3,494 patients from 111 countries 
(sub-group #1)
4,128 patients primarily treated in 
their country of residence
No data on travel distance for 634 
patients
223 patients from 73 countries 
travelled abroad for Rb treatment 
(sub-group #2)
A
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North-
America
North-
America
Africa
LAC
Asia
Africa
LAC
Europe
Asia
52
48
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